chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Back and neck aches and paiins; Back and neck aches and pains; Fever (Temp 99.5); Chills; This spontaneous case was reported by a consumer and describes the occurrence of BACK PAIN (Back and neck aches and paiins), NECK PAIN (Back and neck aches and pains), PYREXIA (Fever (Temp 99.5)) and CHILLS (Chills) in a 77-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 006M20A) for COVID-19 vaccination.     Concurrent medical conditions included Hypertension. Concomitant products included METOPROLOL SUCCINATE (TOPROL) for Hypertension.    On 13-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 15-Feb-2021, the patient experienced BACK PAIN (Back and neck aches and paiins), NECK PAIN (Back and neck aches and pains), PYREXIA (Fever (Temp 99.5)) and CHILLS (Chills). The patient was treated with PARACETAMOL (TYLENOL) ongoing since an unknown date at a dose of 1 dosage form. At the time of the report, BACK PAIN (Back and neck aches and paiins), NECK PAIN (Back and neck aches and pains), PYREXIA (Fever (Temp 99.5)) and CHILLS (Chills) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 15-Feb-2021, Body temperature: 99.5 (High) 99.5.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No relevant concomitant medications reported.
Five days after the vaccine I had recovered from the original symptoms. I woke up during the night with a strong sharp in my left Testicle. When I woke up in the morning the pain was more severe when I moved. It was painful when I moved in certain directions and when I was sitting.  I was tested in Urgent Care and they couldn't find anything wrong. It was isolated to the left side. I have never experienced this pain before. It is still causing me pain and it is a little tender after four weeks.
?Patient received vaccine that was stored improperly. Vaccine was moved from ultra-cold freezer to freezer on 6/17/21. According to guidance from Pfizer, vaccine stored in the freezer after day 17 is considered improperly stored, and the patient will need to be re-vaccinated. IN ADDITION patient received Moderna vaccine for first dose but was erroneously given Pfizer for second dose.
dizziness; This spontaneous case was reported by a consumer and describes the occurrence of DIZZINESS (dizziness) in a 71-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Coronary artery disease and Blood pressure abnormal.    In January 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In February 2021, the patient experienced DIZZINESS (dizziness). At the time of the report, DIZZINESS (dizziness) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant products included medication for blood pressure and heart medication for an unknown indication. Treatment information was unknown.  Reporter stated that the event onset was 1-2 weeks after the dose.   This case was linked to MOD-2021-363353, MOD-2021-363354 (Patient Link).
Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 65-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 09Sep2022 at 20:00 as dose 5 (booster), single (Batch/Lot number: unknown) at the age of 64 years, in right arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown), as dose 3 (booster), single (Batch/Lot number: unknown) and as dose 4 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Hyperthyroid" (unspecified if ongoing). There were no concomitant medications. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "not recovered" and all described as "Treatment of COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (unspecified date) Positive, notes: COVID 19 Treatment; (07Oct2022) Negative, notes: tested negative 2 days after completing Paxlovid on 07Oct2022; (10Oct2022) Positive, notes: tested positive this morning 10Oct2022. Therapeutic measures were taken as a result of drug ineffective, covid-19.  Clinical course- Patient received vaccine. Patient did not received any other medication in 2weeks. Patient received Paxlovid from 30sep2022 to 04Oct2022 for Covid-19 treatment. Patient tested negative 2 days after completing Paxlovid on 07Oct22. She started to feel like I was getting a head cold on 09Oct22 and tested positive this morning 10Oct22.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Left arm was so sore I could barely lift it, which was expected but later in the day I experienced extreme fatigue, aches in my muscles and joints, severe headache, nausea and fever of 100.5 for several hours.  Tylenol did help alleviate some of the symptoms. Some symptoms persist today, 2nd day post vaccine, such as headache, fatigue  and arm soreness.
Arm was swelling and hot to touch on Monday 8/31/20. Arm was hurting. No fever. Flu shot given on Saturday 8/29/20
numbness in face, neck and cheeks; tingling in face,neck and cheeks; Sick; Injection site swollen; achiness; This spontaneous case was reported by a consumer and describes the occurrence of HYPOAESTHESIA (numbness in face, neck and cheeks), PARAESTHESIA (tingling in face,neck and cheeks), ILLNESS (Sick), MYALGIA (achiness) and INJECTION SITE SWELLING (Injection site swollen) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced HYPOAESTHESIA (numbness in face, neck and cheeks), PARAESTHESIA (tingling in face,neck and cheeks), ILLNESS (Sick), MYALGIA (achiness) and INJECTION SITE SWELLING (Injection site swollen). At the time of the report, HYPOAESTHESIA (numbness in face, neck and cheeks), PARAESTHESIA (tingling in face,neck and cheeks), ILLNESS (Sick), MYALGIA (achiness) and INJECTION SITE SWELLING (Injection site swollen) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication reported. No treatment medication reported.   This case was linked to MOD-2021-314649 (Patient Link).
3:15 PM CONFUSION AND SLURRING NOTED. HEADACHE PRESENTED. T-98.9, BP-114/78, P-82. 3:40 PM CONFUSION AND SLURRING RESOLVED. HEADACHE STILL PRESENT 8/10 ON PAIN SCALE. 5:00 PM ACETAMINOPHEN 650 MG TAKEN WITH 12 OZ OF GATORADE. 5:45 PM HEADACHE RESOLVED.
Red, warm to touch 4" size area on left upper arm. Small hard lump in middle.
Lightheadedness, chills, fever, headache, body aches, fatigue, cough, injection sight pain
The patient received his vaccine on Monday 2/1/21. The patient did not complain of any ADRs or fever immediately following the injection. However, the next day he had a temperature of 101.3 F. Since the patient was febrile, he was given rapid COVID tests, which was negative. Patient received acetaminophen. He was not in distress. He had no complaints otherwise.
Moderna COVID?19 Vaccine EUA Numbness in my arm, headache, very tired
Have been suffering from extreme fatigue/exhaustion since receiving the vaccine. Also shortness of breath from even minor exertion.
area vesicular on face 11/18/99, crusted w/scab 11/19/99 & now w/cluster of vesicles rt abd area, fluid filled no temp/no other s/s;
This is a spontaneous report received from contactable reporter(s) (Consumer or other non-HCP). The reporter is the patient. A 75-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), as dose 2, single (Batch/Lot number: unknown), in left arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient had no relevant medical history. The patient's concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset 2023, outcome "unknown" and all described as "COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Positive. Therapeutic measures were taken as a result of drug ineffective, covid-19 included PAXLOVID from 07Apr2023 to 10Apr2023 (lot number: GJ3474).   Clinical course: No known allergies. It was unknown whether other medication taken in 2 weeks or not.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Aches (neck, elbow) Temperature 102. 0 - BP: 120 / 59. 102 Pulse
3 to 4 days post vax; pt devel an infection @ the site of Tertramune admin; pt required incision and draining of the site w/ treatment by antibiotic.  1 of 2 pt  to have inject site infection;by 9/3/96 small pustule head at inj site opened;
HCP calling to report administration of VAQTA during temperature excursion on 7/14/22; This spontaneous report has been received from a nurse, regarding a 2-year-old male patient. The patient's pertinent medical history, current conditions, previous drug reactions or allergies, and concomitant medications were not reported.  On 14-JUL-2022, the patient was vaccinated with an improperly storage dose of hepatitis A vaccine, inactivated (VAQTA) intramuscular injection, 0.5 milliliters, once as prophylaxis (route and anatomical location of administration, lot number and expiration date were not reported) (product storage error). Temperature and period of time of the temperature excursion was not provided.
This spontaneous report was received from a Medical Assistant referring to a patient of unknown age and gender. The patient's medical history, concurrent conditions and concomitant medication were unknown. On an unknown date, the patient was vaccinated with a dose of VARIVAX, injection, lot # M008173, expiration date: 16-FEB-2018, subcutaneously (in the back of the arm). Dose number of strength were not provided. The dose received by the patient had undergone a temperature excursion (experienced on an unknown date). The patient did not experienced any adverse event. It is unknown if there was any relevant laboratory data. This is one of several reports received from the same reporter. Additional information has been requested.
Local site reaction developed within 24 hrs after receiving the vaccine.   Seen about 2 days after the vaccine, it began to fade.  No medications or other treatments given.  Advised patient to follow up if desired.
A week after getting the second dose my smell and taste changed completely, I cannot smell or taste 100%. It smells like humidity. Sometimes when I bend down it smells weird and food tastes horrible. I have lost weight. I have horrible head aches and horrible anxiety. I made like 2 or 3 doctor?s appointments but they cancelled them. Until 2 or 3 weeks ago they were able to see me and they did blood work, urine analysis, brain scan. They sent me with a neurologist. Today I am going to pick up my tests results. I also feel like I have a cold. They did not give me any medications. Also, my nose feels stuffed.
I have negative IgG antibody after Pfizer BioNTech vaccine; This is a spontaneous report from a contactable physician. A patient of unspecified age and gender received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, Lot number was not reported), via an unspecified route of administration on an unspecified date at single dose for COVID-19 immunization. The patient medical history and concomitant medications were not reported. The patient underwent lab tests and procedures which included sars-cov-2 antibody test: negative. The patient experienced she have negative IgG antibody after PFIZER BIONTECH vaccine (SARS-COV-2 antibody test negative) on an unspecified date. The outcome of event was unknown.  No follow-up attempts possible. No further information expected.
had nausea, vomiting, rib pain for 2 days. muscle aches, hot flashes,cold chills, had an episode of elevated pulse ratefor 50 minutes. fatigue.  some lasting for 4 days after
I received a rash within 5 minutes of having the vaccine. It started to spread to my back and chest. The pharmacist called the ambulance and gave me Benadryl. I went to the ER, and they kept me for 5 hours. They also gave me IV steroids. My throat also felt a little tough to swallow. I went and saw my doctor and he prescribed steroids for the rash as well.
The patient received dose from vial beyond 30-day use by date; The patient received dose from vial beyond 30-day use by date; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (The patient received dose from vial beyond 30-day use by date) and PRODUCT STORAGE ERROR (The patient received dose from vial beyond 30-day use by date) in a 45-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 037C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 09-Jun-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 09-Jun-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (The patient received dose from vial beyond 30-day use by date) and PRODUCT STORAGE ERROR (The patient received dose from vial beyond 30-day use by date). On 09-Jun-2021, EXPIRED PRODUCT ADMINISTERED (The patient received dose from vial beyond 30-day use by date) and PRODUCT STORAGE ERROR (The patient received dose from vial beyond 30-day use by date) had resolved. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Date of refrigeration was on 7-may-2021. Concomitant medication use was unknown Treatment information was unknown
Information has been received from a physician and a practice manager referring to a patient of unknown age and gender. On 17-SEP-2014, the patient was vaccinated with an improperly stored dose of RECOMBIVAX HB 10 microgram/1 ml (lot# J010613, expiration date 11-JUN-2016). No adverse effects were reported. This specified lot number vaccine was exposed to temperature excursion once. The total cumulative excursion time (hour), the lowest recorded temperature (Fahrenheit degree/Celsius) and the type of excursion (R/F) for each time were 6204, unknown and R. The storage criteria was refrigerator (R). This is one of several reports received from the same source. Additional information has been requested.
Experienced 'cold' symptoms on 03/29/2021 , had possible exposures Tested positive for Covid 19 on  03/31/2021 and 04/02/2021
This case was reported by a pharmacist via out of hour services and described the occurrence of fatigue in a female patient who received SHINGRIX for prophylaxis. On an unknown date, the patient received the 1st dose of SHINGRIX. On an unknown date, less than a year after receiving SHINGRIX, the patient experienced fatigue and general body pain. On an unknown date, the outcome of the fatigue and general body pain were unknown. It was unknown if the reporter considered the fatigue and general body pain to be related to SHINGRIX. Additional details were provided as follows: The age at the vaccination was not reported. The pharmacist left a message on after hours voice mail stating patient's husband came in 2 weeks before the date of reporting and reported that after getting her first shot of SHINGRIX she was in bed for 2 days. The patient had no fever. The patient had extreme fatigue and all of her upper body was extremely sore. No further information was left on after hours voice mail.
Vaccine administered after more than 1 temperature excursion; Vaccine administered after more than 1 temperature excursion; This spontaneous case was reported by an other health care professional and describes the occurrence of POOR QUALITY PRODUCT ADMINISTERED (Vaccine administered after more than 1 temperature excursion) and PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccine administered after more than 1 temperature excursion) in a 43-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 041L20A) for COVID-19 vaccination.     No Medical History information was reported.    On 12-Jan-2021 at 9:56 AM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 12-Jan-2021 at 9:56 AM, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Vaccine administered after more than 1 temperature excursion). On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccine administered after more than 1 temperature excursion). At the time of the report, POOR QUALITY PRODUCT ADMINISTERED (Vaccine administered after more than 1 temperature excursion) and PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccine administered after more than 1 temperature excursion) outcome was unknown. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   The age of patient was provided as 43.35    Concomitant products were not provided.  On 12-Jan-2021,, Excursion time was 08,09 AM temperature was 34, 34 total doses given for the day was 30, condition of vaccine prior to administration was not frozen, vaccine was moved to fridge on 08-Jan-2021 vial was moved to clinic on 12-Jan-2021.  3 vials were sent to clinic. Vaccine BUD date was 02 Feb 2021  The vials were only punctured right before administration and all doses were drawn from the vial due to high-pace clinic.  Temperature recordings were taken using a brand traceable temperature monitor at every hour.  After administration, the vial was returned to the freezer/refrigerator, or maintained at room temperature.  It was reported that the patient was administered with vaccines that experienced more than 1 temperature excursion during 33 weeks in 2021. The HCP explained that each time a vial was put into a cooler, there was a period of 1 hour or 1 and half hour approximately, when the temperature data logger registered 34 or 35 degree F.  Treatment medications were not reported
Initial and follow up information received from a healthcare professional on 06 May 2012 and 15 May 2012. This case was cluster of 8 patients those experiencing adverse events after receiving ADACEL vaccine lot number C4051BA on same center and reported by same reporter. The 8 patient received ADACEL vaccine (Lot number C4051BA, exp. June 20, 2014), who have complained of swelling at the site of injection, swollen lymph nodes, sore armpits, nausea, aching, and site warm to touch and itching, the vaccines were given on 2 May 2012 (route and site of administration was not reported). A few members were sent to a local MTF, one member was given a course of antibiotics, and two were told to follow up at this week. This appears to be a high number of members having the same symptoms in such a short period of time. A total of 10 received the vaccine on this day, and 8 have reported two or more of the above symptoms. The next day 3 returned to clinic. Two patients complained of pain, heat, swelling and redness at the site along with swelling of an axillary node. They were sent to Sick Call. One was given antibiotics, both were much better in 2-3 days. The third patient complained of flu like symptoms with fever and sweats along with the large, local reaction symptoms. He was better systemically in a couple of days and by 2 weeks he had a small knot left at the site. They called the remaining 6 patient's who were there on 5/2. 5 of them reported more swelling, pain and redness than they usually got with Td. The 6th had nothing to report. Documents held by sender: none.
This is a spontaneous report from a contactable consumer received via the non-clinical study program Pfizer. This reporter reported similar events for 2 patients. This is the second of 2 reports. A male patient of unspecified age and ethnicity received PREVNAR single dose via an unspecified route of administration on an unspecified date. Relevant medical history and concomitant medications were not reported. The patient experienced pinkish rash all the way down inside of his arm on an unspecified date with outcome of unknown. Unspecified therapeutic measures were taken as a result of pinkish rash all way down inside of his arm. Follow-up (05FEB2015): Follow-up attempts completed. No further information expected.
Rash at the injection site after receiving the first dose of Moderna COVID-19 vaccine; little soreness after receiving the second dose of Moderna COVID-19 vaccine; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE RASH (Rash at the injection site after receiving the first dose of Moderna COVID-19 vaccine) and VACCINATION SITE PAIN (little soreness after receiving the second dose of Moderna COVID-19 vaccine) in a 74-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 032L20A and 003A21A) for COVID-19 vaccination.     No Medical History information was reported.   On 21-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 25-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 26-Feb-2021, the patient experienced VACCINATION SITE RASH (Rash at the injection site after receiving the first dose of Moderna COVID-19 vaccine) and VACCINATION SITE PAIN (little soreness after receiving the second dose of Moderna COVID-19 vaccine). At the time of the report, VACCINATION SITE RASH (Rash at the injection site after receiving the first dose of Moderna COVID-19 vaccine) and VACCINATION SITE PAIN (little soreness after receiving the second dose of Moderna COVID-19 vaccine) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Treatment medication included Tylenol. No concomitant medications were not provided by reporter.